Economic burden associated with the use of generic antiepileptic drugs in the United States

Epilepsy and Behavior

Volumn 18, Issue 4, 2010, Pages 437-444

  Helmers, Sandra L ^a   Paradis, Pierre Emmanuel ^b   Manjunath, Ranjani ^c   Duh, Mei Sheng ^d   Lafeuille, Marie Hélène ^b   Latrémouille Viau, Dominick ^b   Lefebvre, Patrick ^b   Labiner, David M ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GROUPE D ANALYSE   (Canada)

^c GLAXOSMITHKLINE   (United States)

^d ANALYSIS GROUP   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antiepileptic drugs; Economic analysis; Epilepsy; Generic substitution

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; PHENYTOIN; PRIMIDONE; ZONISAMIDE;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG USE; ECONOMIC ASPECT; EPILEPSY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; OPEN STUDY; PATIENT SELECTION; UNITED STATES;

ANTICONVULSANTS; DATABASES, FACTUAL; DRUG UTILIZATION; DRUGS, GENERIC; EPILEPSY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 77955566008     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.05.015     Document Type: Article

References (34)

1. OECD. Panorama de la santé. Les indicateurs de l'OCDE, Dépenses de santé et financement, 5-4. Dépenses pharmaceutiques. 2007. Available at: Accessed: February 24, 2008. http://oberon.sourceoecd.org/vl=1764273/cl=27/nw=1/rpsv/health2007_fre/5-4.htm.
2. Kyle M.K. Pharmaceutical price controls and entry strategies. Rev Econ Statist 2007, 89:88-99.
3. Ess S.M., Schneeweiss S., Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003, 21:89-103.
4. Anon Prescription drug trends 2008, Kaiser Family Foundation, Menlo Park.
5. Historical national health expenditure accounts 2009, CMS Centers for Medicare and Medicaid Services, Available at: http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage. Accessed: July 9, 2009.
6. McManus P., Birkett D.J., Dudley J., Stevens A. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. Pharmacoepidemiol Drug Saf 2001, 10:295-300.
7. Medicare modernization update 2005, CMS Centers for Medicare and Medicaid Services, Available at: http://www.cms.hhs.gov/mmaupdate/. Accessed: December 20, 2008.
8. Besag F.M. Is generic prescribing acceptable in epilepsy?. Drug Saf 2000, 23:173-182.
9. Crawford P., Feely M., Guberman A., Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006, 15:165-176.
10. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003, 25:1578-1592.
11. Sander J.W. The use of antiepileptic drugs: principles and practice. Epilepsia 2004, 45(Suppl. 6):28-34.
12. Privitera M.D. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr 2008, 8:113-117.
13. Andermann F., Duh M.S., Gosselin A., Paradis P.E. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007, 48:464-469.
14. LeLorier J., Duh M.S., Paradis P.E., et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008, 70:2179-2186.
15. LeLorier J., Duh M.S., Paradis P.E., et al. Economic impact of generic substitution of lamotrigine: projected costs in the United States using findings in a Canadian setting. Curr Med Res Opin 2008, 24:1069-1081.
16. Duh M.S., Andermann F., Paradis P.E., Weiner J., Manjunath R., Crémieux P.Y. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Disease Manage 2007, 10:216-225.
17. Duh M.S., Paradis P.E., Latrémouille-Viau D., et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009, 72:2122-2129.
18. Zachry W.M., Doan Q.D., Clewell J.D., Smith B.J. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009, 50:493-500.
19. Rascati K.L., Richards K.M., Johnsrud M.T., Mann T.A. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009, 29:769-774.
20. Devine S.T., Barron J., Behm A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr Med Res Opin 2010, 26:455-463.
21. Hansen R.N., Campbell J.D., Sullivan S.D. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav 2009, 15:481-485.
22. Labiner D., Paradis P.E., Duh M.S., et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010, 74:1566-1574.
23. Frost F., Hurley J., Petersen H., et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000, 41:1020-1026.
24. Argumosa A., Herranz J.L. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev Neurol 2005, 41:45-49.
25. Jobst B.C., Holmes G.L. Prescribing antiepileptic drugs: should patients be switched on the basis of cost?. CNS Drugs 2004, 18:617-628.
26. Davis K.L., Candrilli S.D., Edin H.M. Prevalence and cost of nonadherence with antiepileptic drugs in adult managed care population. Epilepsia 2008, 49:446-454.
27. Faught E., Duh M.S., Weiner J.R., Guérin A., Cunnington M.C. Nonadherence to antiepileptic drugs and increased mortality. Neurology 2008, 71:1572-1578.
28. Hovinga C.A., Asato M.R., Manjunath R., et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav 2008, 13:316-322.
29. Ettinger A.B., Manjunath R., Candrilli S.D., Davis K.L. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav 2009, 14:324-329.
30. Manjunath R., Davis K.L., Candrilli S.D., Ettinger A.B. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 2009, 14:372-378.
31. Sikka R., Xia F., Aubert R.E. Estimating medication persistency using administrative claims data. Am J Manag Care 2005, 11:449-457.
32. Begley C.E., et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000, 41:342-35.
33. Theodore W.H., Spencer S.S., Wiebe S., et al. Epilepsy in North America: a report prepared under the auspices of the Global Campaign against Epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization [ILAE report]. Epilepsia 2006, 47:1700-1722.
34. Bodenheimer T. High and rising health care costs: Part 1. Seeking an explanation. Ann Intern Med 2005, 142:847-854.